The mice also display a selective facilitation of long-term potentiation (LTP) in the medial perforant path and a selective enhancement in rapid-acquisition spatial memory, phenotypes that are reversed by direct application of a cell-permeant peptide (DNIP) designed to interfere with NCS-1 binding to the dopamine type-2 receptor (D2R).
Evidence for the vestibular, or S2, pocket serving as the initial substrate binding site was provided with the dopamine transporter, in which two dopamine molecules were seen to be necessary for substrate translocation through the cell membrane.
Shah et al. reported decreased dopamine function, as indexed by increased binding of the dopamine D 2/3 ligand 1-123-IBZM 1-123-IBZM 1-123-IBZMm in pathents with majorightrestriatum80].
Both epileptic groups presented elevated binding to the dopamine transporter and low tissue content of dopamine and its metabolites.
In SPECT and PET imaging studies, radioligand binding to the dopamine receptor or transporter reflects the occupancy by dopamine itself or antipsychotics.
Cannabinoids compete with dopamine for the binding sites on the dopamine transporter, and in sufficient quantity they win, which frees up more dopamine to slow down the speed of neurotransmissions.
For instance, compared to controls, differences have been identified in the binding potential of the dopamine transporter protein in adults with ADHD [ 11- 13].
The availability of more dopamine made possible by cannabinoids occupying dopamine binding sites on the dopamine transporter causes an increase in available dopamine and a decrease in the speed and frequency of neural stimulation to the midbrain and thus helps manage the symptoms of PTSD, ADD/ADHD.
The current observations suggest that the S100B interaction with the dopamine D2 receptor may fall into this class of S100 binding.
To probe striatal dopamine availability, animals were challenged with the dopamine D2 receptor agonist apomorphine.
